Opko Health Inc. (NASDAQ:OPK) announces that GeneDx, a business unit of OPKO’s BioReference Laboratories division, will be showcasing its leadership in genetic and genomic testing with more than 35 poster and platform presentations at the National Society of Genetic Counselors (NSGC) and the American Society of Human Genetics (ASHG) annual meetings this fall.
At the 36th Annual National Society of Genetic Counselors Meeting taking place September 13-16 in Columbus, Ohio, GeneDx will be presenting original scientific work and participating in ancillary educational sessions. GeneDx has been selected by NSGC to present data in three platform and 19 poster presentations. In addition, GeneDx will be participating in two pre-conference symposia and will be sponsoring an educational lunch session where GeneDx experts will discuss how techniques such as next-generation sequencing can be optimally leveraged as an important tool in genetic variant detection and analysis.
At the American Society of Human Genetics Annual Meeting taking place October 17-21 in Orlando, GeneDx will present research in one podium and twenty poster presentations. GeneDx is also a collaborator on six additional presentations.
“GeneDx continues to demonstrate active engagement with the clinical and scientific community in all aspects of genetic and genomic testing, and we are excited to have been selected to share our robust data and research with the larger genetics community,” said Ben Solomon, MD, FACMG, Managing Director of GeneDx. “Our prominent presence at the NSGC and ASHG meetings this fall underscores the passion our entire team has for contributing to and advancing the field of genomic medicine.”
In addition to participating in this year’s premier fall genetics conferences, GeneDx is also excited to announce the increased flexibility of its sample collection. GeneDx will now offer the option of a U.S. Food and Drug Administration cleared buccal (cheek swab) sample collection kit, which is available for GeneDx’s expansive test menu and patients of any age.
“We are always looking at ways to make providers’ jobs easier, and we will continue to invest in efforts that will help us meet this goal,” said Sean Hofherr, PhD, FACMG, Chief Scientific Officer at GeneDx.
Shares of Opko Health are currently trading at $6.18, down $0.03 or -0.54%. OPK has a 1-year high of $12.15 and a 1-year low of $5.85. The stock’s 50-day moving average is $6.23 and its 200-day moving average is $6.93.
On the ratings front, OPK has been the subject of a number of recent research reports. In a report issued on August 17, Cantor analyst Louise Chen initiated coverage with a Buy rating on OPK and a price target of $20, which represents a potential upside of 222% from where the stock is currently trading. On July 25, Jefferies’ Eun Yang reiterated a Hold rating on the stock and has a price target of $8.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Louise Chen and Eun Yang have a yearly average loss of 8.8% and a return of 5.9% respectively. Chen has a success rate of 43% and is ranked #4493 out of 4635 analysts, while Yang has a success rate of 52% and is ranked #587.
Sentiment on the street is mostly bullish on OPK stock. Out of 4 analysts who cover the stock, 3 suggest a Buy rating and one recommends to Hold the stock. The 12-month average price target assigned to the stock is $12.83, which implies an upside of 107% from current levels.
OPKO Health, Inc. is a diversified healthcare company. It operates through Diagnostics, and Pharmaceutical segments. The Diagnostics segment is consists of the pharmaceutical operates that the company acquired in Chile, Mexico, Ireland, Israel, and Spain and its pharmaceutical research and development operations. The Diagnostics segment is primarily comprised of the clinical and laboratory operations tit acquired through the acquisition of Bio-Reference and OPKO Lab and its point-of-care operations.